Lelly Winduhani Astuti, 051515153025 (2017) PERUBAHAN KADAR SST2 PADA PASIEN GAGAL JANTUNG SETELAH PEMBERIAN TERAPI KOMBINASI ACE-INHIBITORS DAN β-BLOCKERS (Penelitian dilaksanakan di IRNA SMF Kardiologi dan Kedokteran Vaskular RSUD Dr. Soetomo Surabaya). Thesis thesis, UNIVERSITAS AIRLANGGA.

Preview	Text (Abstrak) TFK. 13-18 Ast p Abstrak.pdf Download (72kB) | Preview
	Text (fulltext) TFK. 13-18 Ast p.pdf Restricted to Registered users only until 12 March 2021. Download (1MB) | Request a copy

Abstract

Background: Heart failure caused by declining of heart ability to circulate blood, which lead to compensation mechanism. Continued compensation mechanism induce cardiac remodelling. sST2 is a cardiac biomarker which was expressed in mechanically stretched myocyte. sST2 has a role in myocyte fibrosis and hyperthopy, that caused cardiac remodelling. ACE Inhibitors and and β blockers were recommended for heart failure, prevent remodelling using several mechanism, one of them is lessening myocardial stretch. Objective: This study was aimed to analyze the effect of ACE inhibitors and β-blockers combination therapy on sST2 level, as a cardiac marker, on inpatients with heart failure. Methods: This study was a prospective observational study with one group pretestposttest. 17 patients were collected using consecutive sampling. sST2 were measured before and after combination therapy, after both drugs reach steady state. Ethical committee of RSUD Dr. Soetomo approved this study. sST2 level were examined using ELISA, and statistically processed using Wilcoxon test to compare sST2 pre and post level. Result: From 17 patients, decrease of sST2 level were found in 13 patients. In this study, we found the range of sST2 before therapy were 16.8-2772 ng/nL whereas sST2 level after therapy was 12.9-1299.9 ng/mL. The mean of the decrease was 63.7%. sST2 level were significantly decrease (p=0.017) Conclusion: There was a significant decrease in sST2 level pre and post.

Actions (login required)

View Item